GeoVax Announces U.S. Patent And Trademark Office Issued Patent Number 11,701,418 B2 Titled "Replication-Deficient Modified Vaccinia Ankara (MVA) And Matrix Protein (VP40)"
Portfolio Pulse from Benzinga Newsdesk
GeoVax has been issued a patent titled 'Replication-Deficient Modified Vaccinia Ankara (MVA) And Matrix Protein (VP40)' by the U.S. Patent and Trademark Office. The patent number is 11,701,418 B2.
July 24, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeoVax's new patent could potentially strengthen its intellectual property portfolio and provide a competitive edge in the market.
The issuance of a new patent to GeoVax could potentially strengthen its intellectual property portfolio, providing a competitive edge in the market. This could lead to increased investor confidence and potentially a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100